Tags : Foghorn

Weekly Snapshot (Jul 06 – 10, 2020)

Vartika Singh July 13, 2020

1. LEO Reports the US FDA’s Acceptance of BLA for Tralokinumab to Treat Adults with Moderate to Severe Atopic Dermatitis Published Date: Jul 10, 2020 | Tags: LEO, Reports, US, […]readmore

Biotech

Merck Collaborates with Foghorn to Develop Oncology Therapies Against Transcription

Tuba Khan July 8, 2020

Shots: Foghorn will receive an upfront, development, regulatory and commercial milestones totaling up to $425M as well as royalties on sales of any approved therapy emerges from the collaboration Merck […]readmore

Tags : Foghorn

Weekly Snapshot (Jul 06 – 10, 2020)

Merck Collaborates with Foghorn to Develop Oncology Therapies Against Transcription

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Foghorn

Weekly Snapshot (Jul 06 – 10, 2020)

Merck Collaborates with Foghorn to Develop Oncology Therapies Against Transcription

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company